Arikayce’s Limited Population, Black Box Warning Won’t Limit Launch, Insmed Says
Because it will be initially targeting specialists and a very sick population, the biotech thinks Arikayce will get early usage in its narrowly defined lung infection indication.
You may also be interested in...
Variety Of Impacts COVID-19 Poses For Biopharma Reflected In Earnings Calls
Several firms reporting quarterly earnings this week discussed how the outbreak is affecting supply chains, drug launches and clinical trials.
Finance Watch: Three New Biopharma IPOs In The US With Eight More Entering The Queue
Public Company Edition: IPO performance has been mixed in 2019, but May has been the busiest month this year. Also, Insmed leads recent follow-on offerings and Dynavax restructures.
Keeping Track: Three Oncologics, A New Migraine Preventive, And First LPAD Antibiotic Clear US FDA
The latest drug development news and highlights from our FDA Performance Tracker.